Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point.

Van Putten T, May PR.

Arch Gen Psychiatry. 1978 Apr;35(4):477-80.

PMID:
727898
2.

Subjective response to antipsychotic drugs: failure to replicate predictions of outcome.

Ayers T, Liberman RP, Wallace CJ.

J Clin Psychopharmacol. 1984 Apr;4(2):89-93.

PMID:
6707245
3.
4.

Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.

Hogan TP, Awad AG, Eastwood MR.

Can J Psychiatry. 1985 Jun;30(4):246-8.

PMID:
2861887
5.

Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.

Minami H, Nakahara T, Miyahara A, Nakane Y.

Psychiatry Clin Neurosci. 1997 Aug;51(4):217-22.

6.
7.

Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.

Bartkó G, Herczeg I, Békésy M.

J Clin Psychiatry. 1987 Sep;48(9):363-5.

PMID:
3624207
8.

Subjective response to antipsychotic drugs.

Van Putten T, May PR, Marder SR, Wittmann LA.

Arch Gen Psychiatry. 1981 Feb;38(2):187-90.

PMID:
7212946
10.

Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients.

Steinbook RM, Goldstein BJ, Brauzer B, Jacobson AF, Moreno SS.

J Clin Pharmacol. 1975 Oct;15(10):700-4.

PMID:
1102569
11.

Chlorpromazine levels and the outcome of treatment in schizophrenic patients.

May PR, Van Putten T, Jenden DJ, Yale C, Dixon WJ.

Arch Gen Psychiatry. 1981 Feb;38(2):202-7.

PMID:
7212947
12.

Concordance of multiple assessments of the outcome of schizophrenia. On defining the dependent variable in outcome studies.

Schwartz CC, Myers JK, Astrachan BM.

Arch Gen Psychiatry. 1975 Oct;32(10):1221-7.

PMID:
1180656
13.

Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships.

Clark ML, Ramsey HR, Rahhal DK, Serafetinides EA, Wood FD, Costiloe JP.

Arch Gen Psychiatry. 1972 Oct;27(4):479-83. No abstract available.

PMID:
5072717
14.

The neuroleptic hypothesis: study of the covariation of extrapyramidal and therapeutic drug effects.

Alpert M, Diamond F, Weisenfreund J, Taleporos E, Friedhoff AJ.

Br J Psychiatry. 1978 Aug;133:169-75.

PMID:
354734
15.

A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia.

Hong CJ, Chen JY, Chiu HJ, Sim CB.

Int Clin Psychopharmacol. 1997 May;12(3):123-30.

PMID:
9248867
16.

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.

Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP.

Int Clin Psychopharmacol. 1996 May;11 Suppl 2:55-9. Review.

PMID:
8803661
17.

Total and free plasma neuroleptic levels in schizophrenic patients.

Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P.

Psychiatry Res. 1984 Dec;13(4):285-93.

PMID:
6596586
18.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
19.

Predicting outcome of antipsychotic drug treatment from early response.

May PR, Van Putten T, Yale C.

Am J Psychiatry. 1980 Sep;137(9):1088-9.

PMID:
7425161
20.

Subjective response to neuroleptics in schizophrenia.

Awad AG.

Schizophr Bull. 1993;19(3):609-18.

PMID:
7901897

Supplemental Content

Support Center